Qube Research & Technologies LTD Arcus Biosciences, Inc. Call Options Transaction History
Qube Research & Technologies LTD
- $61.9 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding RCUS
# of Institutions
187Shares Held
49.2MCall Options Held
204KPut Options Held
149K-
Black Rock Inc. New York, NY9.9MShares$137 Million0.0% of portfolio
-
State Street Corp Boston, MA4.9MShares$67.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.79MShares$66.3 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA2.88MShares$39.9 Million0.52% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct1.91MShares$26.5 Million0.09% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $999M
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...